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ABSTRACT
Background: Rotavirus (RV) is worldwide an important cause of acute gastroenteritis (AGE) in infants
and young children. There is no specific treatment for AGE caused by RV (RVGE) but since 2006 two safe
and effective vaccines have been available. RV vaccination was included in the national immunization
program (NIP) of Latvia in 2015 with full reimbursement, and within the first year a coverage of 87% was
achieved. This surveillance study was carried out to investigate the proportion of RVGE among AGE
episodes in Latvia up to the inclusion of RV vaccination in the NIP to provide a basis for future
assessments of the impact of RV vaccination.
Methods: Prospective, one-year observational study of children younger than 5 years presenting with AGE in
the primary care setting. At first primary care contact, a stool sample was collected and tested for RV using a
rapid, visual immunochromatographic kit. The parents monitored their child’s symptoms over 2 weeks after
the first contact and the investigator recorded these observations during a follow-up phone call. The propor-
tion of RVGE among the AGE cases was estimated and the severity of each AGE casewas assessed based on the
recorded symptoms using the 20-point Vesikari scale. The seasonality of RVGE was also investigated.
Results: Fifty-two primary care investigators collected data on 606 evaluable children with AGE. The
proportion of RVGE was 38.1%. Severe AGE was experienced by 40.7% of the RV-positive and 19.5% of
the RV-negative patients. The rate of hospitalization was 9.1% for the RV-positive and 4.8% for the RV-
negative with no difference in the mean duration of hospital stays. AGE and RVGE both occurred all year
round but with a clearly marked peak only for RVGE, from March to May.
Conclusion: This study underlines that RV is an important cause of AGE in children under 5 years old in
Latvia and that the burden of disease of RVGE in primary care was substantial before inclusion of RV
vaccination in the NIP.
Trial registration: NCT01733849
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Introduction
Acute rotavirus gastroenteritis (RVGE) is a universal disease,
although the etiological role of rotavirus (RV) is often unrecog-
nized as it requires confirmation by laboratory test.1–3 RV is
transmitted primarily via the fecal-oral route and it attacks and
destroys the enterocytes of the intestinal villi, thereby diminishing
their absorptive capacity and causing diarrhea.1 Transmission
occurs either directly from person-to-person or indirectly via
contaminated surfaces, where the RV may persist for extended
periods and be transmitted to susceptible individuals.4
Clinically, the disease can vary from subclinical, asympto-
matic forms, which are more common in older children and
adults, to acute gastroenteritis (AGE) with vomiting, watery
diarrhea and fever.5 In some cases, the disease can progress
with severe diarrhea accompanied by vomiting and risk of
dehydration, which may rapidly become irreversible and fatal
if not corrected adequately from the beginning.3,5 The progres-
sion to life-threatening dehydration is unpredictable, as there
are no recognized risk factors for such progression.3
Newborns are partly protected by maternal antibodies and
the highest incidence rate is registered between 6 and
24 months of age, with the greatest risk of developing severe
disease under age 12 months.3,5
Seasonality is a key feature of RV infectionswith peak incidence
related to latitude and climate and, in most developed countries, a
higher incidence of RVGE in cooler and drier seasons.6,7
RV infections are most certainly underreported, as RV is
often not distinguished from other causes of AGE, even for
patients hospitalized for diarrhea.7 The treatment of AGE is
the same regardless of its cause, so the incentive to do the
testing required for differential diagnostics is rather limited.3
The treatment of AGE is fluid replacement to prevent dehy-
dration due to vomiting and diarrhea and zinc treatment,
which may shorten the duration of diarrheal episodes.1 Since
about 2006, 2 effective and safe vaccines against rotavirus
have been available and recommended by WHO from 2007
but the uptake across the world has been highly variable.1 One
reason for limited uptake in developed countries is uncer-
tainty about the cost-effectiveness of the vaccines, partly
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because the knowledge about the actual burden of disease is
limited.8
In Latvia, RVGE is a notifiable disease, but stool samples are
not routinely tested for RV in primary care settings and most
existing RVGE incidence estimates are based on hospital data.
The RVGE incidence increased from 84 per 100,000 in 2007 to
169 per 100,000 in 2011.9 The highest incidence (20–30% above
the national average) was observed in the regions around the
two largest cities, Riga and Daugavpils.4 Latvia established
national rotavirus vaccination recommendations in 2010 and
fully reimbursed rotavirus vaccination was included in the
National Immunization Program (NIP) from January 1, 2015.
Within the first year of this full reimbursement, a coverage of
87% was achieved whereas coverage was < 5% when the vac-
cine was available in the private market from 2007.10
The objective of the present study conducted in Latvia was
to investigate the burden of RVGE in primary care settings for
infants and children under 5 years old prior to the introduc-
tion of RV vaccination in the NIP. We focused on estimating
the proportion of RVGE among all AGE cases presenting in
primary care, their severity as summarized by the Vesikari
scale,11 the proportion of RVGE cases in primary care referred
to hospital admission and the seasonality of RVGE episodes.
The data reported here may therefore serve as baseline data
for future studies of the impact of vaccination on the disease
burden and of the cost-effectiveness of vaccination.
Results
Demographic characteristics
Data were evaluable for 606 enrolled children (Table 1). Of
these, 21 were enrolled more than once (and counted as sepa-
rate cases), 7 of whom were RV-positive. The gender distribu-
tion was approximately equal overall and in each RV status
group. The median age was a little higher in the RV-positive
than in the RV-negative group, 24 months versus 20 months.
Proportion of RVGE cases, overall and per age group
Among the 606 AGE cases, 231 (38.1%, 95% CI: 34.2–42.1%)
were RV-positive. The proportion of RV-positive per age
group (derived from Table 2), increased from 19.5% (9/46)
in the infant group (0–5 months), to 42.8% (119/278) in the
oldest group (24–59 months). The number of RVGE cases was
similar in the group under 24 months old and in the group
from 24 to 59 months, 112 and 119, respectively, but the
proportion of RV-positive relative to all AGE cases was
lower in the group under 24 months, 34.1% (112/328).
Clinical characteristics and severity
The severity of the AGE episode by age group and RV status
is described in Table 2. Overall, 40.7% (94/231) RV-positive
and 19.5% (73/375) RV-negative children experienced severe
AGE (Vesikari score ≥ 11; p < 0.001). The same trend was
seen within each of the separate age groups, with the statis-
tical significance of the difference depending on the number
of individuals in the age group. The most substantial
differences were seen in the age groups 6–11 and
12–23 months, where about half the RV-positive and a fifth
of the RV-negative children had experienced severe AGE,
while there was no difference according to RV-status in the
proportion of infants (0 to 5 months) with severe AGE. In
the RV-negative patients, the proportions with severe AGE
did not vary with the child’s age, but in the RV-positive
patients there was a marked peak of severity in the group
of 6 to 23 months old (similar in both subsets, from 6 to 11
and from 12 to 23 months).
Table 3 summarizes details of the symptoms experienced,
on which the aggregate Vesikari severity score is based. All the
symptoms were either more frequent, more severe or/and of
longer duration in the RV-positive than in the RV-negative
patients. The logistic regression models showed an association
between dehydration (odds ratio (OR): 2.06, p < 0.001), fever
(OR: 2.03, p < 0.001), vomiting (OR: 1.45, p = 0.048) and
Vesikari score ≥ 11 (OR: 2.80; p < 0.001) and RV infection as
the cause of AGE.
Proportion of hospitalizations among AGE cases
Among the 606 children in the study, 39 were hospitalized.
The rate of hospitalization was 9.1% (21/231) and 4.8% (18/
375) for the RV-positive and RV-negative patients,









Gender (male/female) (%) 55.8/44.2 50.9/49.1 52.8/47.2
Age at GP pediatrician visit (months)
Mean (SD) 26.5 (14.72) 23.52 (15.68) 24.66 (15.38)
Median (range) 24 (0–58) 20 (0–59) 21 (0–59)
Underlying medical condition; n(%)
Prematurity 7 (3.0) 9 (2.4) 16 (2.6)
Pulmonary disease 5 (2.2) 6 (1.6) 11 (1.8)
Congenital disease 2 (0.9) 1 (0.3) 3 (0.5)
Gastrointestinal disease 2 (0.9) 1 (0.3) 3 (0.5)
Other 5 (2.2) 5 (1.3) 10 (1.7)
No condition 209 (90.5) 353 (94.1) 562 (92.7)
SD = Standard deviation





Age (months) Severity (Vesikari Score) n % n % p-values
0–5 Mild (1–6) 2 22.2 21 56.8 0.1510
Moderate (7–10) 6 66.7 12 32.4
Severe (≥ 11) 1 11.1 4 10.8
6–11 Mild (1–6) 4 16.0 27 42.2 0.0067
Moderate (7–10) 9 36.0 26 40.6
Severe (≥ 11) 12 48.0 11 17.2
12–23 Mild (1–6) 13 16.7 42 36.8 < 0.0001
Moderate (7–10) 24 30.8 46 40.4
Severe (≥ 11) 41 52.6 26 22.8
Missing* 0 - 1 -
24–59 Mild (1–6) 25 21.0 75 47.2 < 0.0001
Moderate (7–10) 54 45.4 52 32.7
Severe (≥ 11) 40 33.6 32 20.1
Overall Mild (1–6) 44 19.0 165 44.1 < 0.0001
Moderate (7–10) 93 40.3 136 36.4
Severe (≥ 11) 94 40.7 73 19.5
Missing* 0 - 1 -
* Lost to follow-up; RV: Rotavirus; p-values = Result of Fisher’s exact test of the
difference in severity according to RV status
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respectively, with overlapping CIs (a borderline significant
difference overall [p = 0.0485], see Table 4). The number of
days in hospital was not significantly different according to
RV-status, with a mean and median of 4.1 and 4 days, respec-
tively, in the RV-positive group and 3.1 and 3 days, respec-
tively, in the RV-negative group.
A multivariate, stepwise logistic regression analysis of the
determinants of hospitalization of the AGE cases was performed.
Based on the results of univariate analyses of the risk factors for
hospitalization, the saturated model included the following vari-
ables: Vesikari severity score (≥ 11 vs. < 11), gender, age (24–
59 months, 12–23 months, 0–11 months) and RV-status
(Table 5). In the multivariate analysis, only the Vesikari severity
score was statistically significant (odds ratio = 21.34, p < 0.001),
whereas age, gender and RV-status in itself had no independent
impact on the risk when controlling for the other factors.
Seasonal distribution of RVGE
AGE and RVGE occurred throughout the year in this Latvian
population of infants and young children but in each age
group there was a marked seasonality in the proportion of
RVGE cases relative to all AGE cases (Figure 1), which peaked
in the months March to May 2014 with proportions of around
56% overall. The minimum proportion of RVGE relative to all
AGE cases was observed in October 2013 with 24.5%. The
absolute number of RVGE cases per month ranged from 9 in
August 2013 to 35 in April 2014.
Discussion
Until now, very limited information on the burden of RVGE
in primary care settings in Latvia has been available. Our
study underlines that RV is an important cause of AGE
cases presenting in primary care in Latvia, causing the most
severe forms of AGE disease and therefore requiring hospita-
lization more frequently than for AGE cases with other
causes. For equally severe AGE cases, the RV status was not
determinant for the risk of being admitted into hospital.
A companion study based on the same protocol was per-
formed in Bulgaria with data collection during the calendar
year 2013.12 The overall proportion of RV-positive cases was
25.5% in Bulgaria compared with 38.1% in Latvia but both
studies found that the proportion of RV-positive cases
increased linearly with age and more than doubled for chil-
dren aged 24–59 months compared to the youngest infants
aged 0–5 months. The severity assessments were very different
in the two studies. In the Bulgarian study, the proportion of
severe cases (Vesikari score ≥ 11) was 81.8% for the RV-
positive and 54.6% for the RV-negative cases, compared
with 40.7% and 19.5%, respectively, in the present study. In
Bulgaria, the hospitalization rate was 20.1% for RV-positive
and 1.5% for RV-negative cases, compared with 9.1% and
4.8%, respectively, in Latvia. This illustrates another finding
in the Bulgarian study, namely that both the RV-status and
the Vesikari score of the cases were independent risk factors
for hospitalization, so even controlling for the severity of the
case the child’s RV-status had a significant impact on the risk
of hospitalization. By contrast, only a severe Vesikari score
was found to be a significant risk factor for hospitalization in





Symptom n % n %
Diarrhea
Yes 227 98.3 370 98.9
No 4 1.7 4 1.1
Missing 0 - 1 -
Number of stools per day (maximum)
1–3 20 8.8 51 13.8
4–5 104 45.8 195 52.7
≥ 6 103 45.4 124 33.5
Days of diarrhea
1–4 139 61.2 258 69.7
5 44 19.4 41 11.1
≥ 6 44 19.4 71 19.2
Vomiting
Yes 158 68.4 199 53.2
No 73 31.6 175 46.8
Missing 0 - 1 -
Number of vomiting episodes per day (maximum)
1 20 12.7 52 26.1
2–4 102 64.6 115 57.8
≥ 5 36 22.8 32 16.1
Days of vomiting
1 64 40.5 99 49.7
2–4 91 57.6 94 47.2
≥ 5 3 1.9 6 3.0
Fever
Yes 182 78.8 227 60.7
No 49 21.2 147 39.3
Missing 0 - 1 -
Temperature
37.1–38.4°C 40 22.0 80 35.2
38.5–38.9°C 65 35.7 71 31.3
≥ 39.0°C 77 42.3 76 33.5
Dehydration
Degree of dehydration
No dehydration 115 49.8 251 67.1
Mild/moderate (1–5%)** 103 44.6 116 31.0
Severe (≥ 6%)** 13 5.6 7 1.9
Missing 0 - 1 -
Type of treatment*
Rehydration in polyclinic 50 21.6 40 10.7
Hospitalization 21 9.1 18 4.8
*: Type of treatment are not substitutes, each patient may have both,**: The
percentages indicate the amount of weight loss.21
Table 4. Number of hospitalizations by rotavirus (RV) status and age group.
RV-positive (N = 231) RV-negative (N = 375)
Age (months) N n % 95% CI N n % 95% CI p-value
0–5 9 0 0.0 0.0–33.6 37 1 2.7 0.1–14.2 1.0
6–11 25 2 8.0 1.0–26.0 64 3 4.7 1.0–13.1 0.6173
12–23 78 10 12.8 6.3–22.3 115 10 8.7 4.2–15.4 0.6083
24–59 119 9 7.6 3.5–13.9 159 4 2.5 0.7–6.3 0.0813
All 231 21 9.1 5.7–13.6 375 18 4.8 2.9–7.5 0.0485
CI: confidence interval
Table 5. Estimated odd ratios and p-values of the fitted logistic regression
model for the possible risk factors for hospitalization of acute gastroenteritis
patients.
Model Risk Factor p-value OR 95% CI of OR
Saturated Vesikari ≥ 11 vs < 11* 0 .0001 21.341 8.003–56.909
Female vs male* 0.4313 0.753 0.371–1.527
Age 12–23 vs 0–11 months* 0.2815 1.744 0.634–4.797
Age 24–59 vs 0–11 months* 0.7840 0.863 0.302–2.467
RV-positive vs RV-negative* 0.9711 0.987 0.481–2.023
Final Vesikari ≥ 11 vs Vesikari < 11* 0 .0001 22.189 8.508–57.874
CI: confidence interval; OR; odds ratio; *reference category
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this Latvian study. Among the potential explanations of the
divergent observations in the two countries are that the epi-
demiology of RV infections may be dissimilar and that health-
care at the local level may be organized differently; in Latvia,
parents may go directly to the hospital to seek care for a sick
child and this may suggest that the more severe cases of
RVGE are seen less often in primary care.
Our observations are broadly similar to the findings of a
number of other studies carried out in primary care settings in
European countries.13–19 The REVEAL study18 which
included 6 Western European countries reported an overall
proportion of 53% with severe disease in RV-positive AGE
patients. The ratio of RV-positive/RV-negative AGE patients
with dehydration was about 1 in Belgium and the UK, but
1.82 in France, 5.54 in Germany, 3.27 in Italy, 3.47 in Spain
and 2.18 in Sweden. The proportion of hospital referrals for
RVGE varied from 13.0% (relative risk (RR) compared to
non-RV AGE = 3.37) to 57.1% (RR = 2.10). Another notice-
able difference from our findings is that the REVEAL study
showed that 33–68% of children with AGE who first pre-
sented in a primary care setting subsequently required med-
ical attention in another medical setting. We observed that
15% received rehydration in a polyclinic and that 6.4% were
hospitalized. In the REVEAL study, up to 2/3 of all hospita-
lizations of AGE cases were due to RV 18 here it was 53.8%
(21/39). It is difficult to assess whether these differences have
any other meaning than random variation but there are
clearly differences in treatment patterns between countries.
The proportion of RV-positive among all the AGE cases
recorded peaked in the months March to May 2014 indicating
seasonality of RV infections, a pattern which is not expected
for AGE infections of other causes. This is in line with the
conventional notion that seasonality of RV infections is char-
acteristic of upper-middle and high income developed coun-
tries with a temperate climate.20 However, to reach a firm
conclusion about the possible seasonality of RV infections in
Latvia before widespread RV vaccination would require
surveillance data for several years. Such analyses would also
allow examination of the potential impact of RV vaccination
on the seasonality of infections which has been observed in
some countries, with delay of onset, shorter duration and
dampening of peaks.21
It is clear that estimating the burden of RVGE by examin-
ing only AGE cases presenting in primary care does not give a
complete picture of the burden of disease caused by RV,
because most of the milder cases will be taken care of in the
home without any medical attention. For Europe, a systematic
review thus estimated that the proportion of RVGE cases
receiving no medical attention varied between 25% and
51%.22
Our results must be interpreted with caution as the study
was limited by a number of factors. The 52 study centers were
located throughout Latvia with about 40% in the regions
surrounding the largest cities where the RVGE incidence
based on hospital data has been estimated to exceed the
national average by some 20–30%. Apart from these data,
we are not able to assess the representativeness of the primary
care units selected and, as a consequence, the generalizability
of the findings to the whole country is uncertain.
Another limitation of the study was that the severity rating
was done by the investigator in an informal way during the
follow-up phone call with the parents and based on the
parents’ recall about the number, severity and duration of
the episodes with symptoms. It is not possible to assess the
accuracy of the parents’ recall but they had not received prior
instructions to record each episode although they had been
informed that they would be enquired about this. A scoring
manual prepared for use of the Vesikari scale in clinical trials
presupposes parent completion of daily diary cards and strin-
gent control by specially trained study clinicians23 but adop-
tion of such a strict protocol was not considered necessary for
this study. The same informal severity scoring approach was
used in the companion study in Bulgaria12 and we have no
obvious explanation for the striking difference in the average
Figure 1. Seasonal distribution of acute gastroenteritis (AGE) cases and percentage of rotavirus-positive (RV+) cases by age group (months).
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severity scores observed in the two studies. As mentioned in
the introduction, Latvia included fully reimbursed vaccination
in the NIP in 2015. Observational impact studies in several
industrialized countries have reported substantial reductions
in disease burden occurring just a few years after implemen-
tation of RV vaccination, with some evidence also of herd
immunity for unvaccinated older children and adults.1,24
Future epidemiological studies may show if the impact of
increased coverage of RV vaccination in Latvia will be similar
to that observed elsewhere despite the substantially increased
RVGE incidence in the years prior to this change of the NIP.
Such studies would require collection of data covering several
years before and after widespread coverage of vaccination to
enable a thorough analysis of the impacts of the vaccination
strategy on the seasonal timing, geographical distribution and
amplitude of RV infection in the susceptible populations. The
present study with data collection over just one year in pri-
mary care is too limited to serve this purpose and must be
seen as just a modest step in describing the epidemiology of
RV in Latvia before general uptake of RV vaccination.
Conclusion
This study of the proportion of AGE cases caused by RV
infection in primary care in Latvia underlines that RV is an
important cause of AGE and that RVGE more often is severe
and leads to dehydration requiring treatment than AGE with
other causes. Hospitalization for AGE-related symptoms was
also more frequent RV-positive children.
Materials and methods
Study design
This prospective, active surveillance study (NCT01733849)
was carried out with patient recruitment and data collection
from July 2013 to the end of June 2014 in 52 primary care
units throughout Latvia. The study was purely observational
and no clinical management instructions were included. All
clinical management including any decision about hospitali-
zation was based exclusively on the clinical judgment of the
pediatrician consulted without instructions or other influence
from the study design.
Approximately 40% of the primary care units were located
in the regions of the two largest cities (Riga and Daugavpils),
the rest were located in rural areas. The number of units
included was based on the targeted sample size and workload
feasibility considerations, considering that each unit would be
able to include 15–20 AGE cases over the 12-month recruit-
ment period. Each primary care unit was instructed to enroll
presenting eligible AGE patients as a function of the number
of AGE cases in children under 5 years old it had reported
during the preceding year. Thus, units which had had rela-
tively few AGE cases the year before were instructed to seek to
enroll each eligible AGE case presenting, whereas units which
had treated relatively many AGE cases the year before were
instructed to seek to enroll every second or third, etc.
Children could be included more than once provided that
they had been symptom-free at least 14 days since the end
of the previous episode. With this provision, each repeat
episode was recorded as a new case.
Study population and case definition
Children younger than 5 years old, whose parents consulted
their primary care physician for the child’s AGE, either in the
clinic or as a home visit, were eligible for enrolment. A case of
AGE was defined as 3 or more loose stools and/or 2 or more
vomiting episodes within a 24-hour period with onset of
symptoms ≤ 14 days before the consultation. There was no
specific exclusion criterion and children were included if they
met the definition of an AGE case and the parents gave
informed consent. This study was conducted in accordance
with Good Clinical Practice guidelines and the Declaration of
Helsinki and was approved by the national independent ethics
committee in Latvia. Written informed consent was collected
from parents/guardians before enrolment.
Data collection
During the consultation or home visit, details of the infant or
child were recorded. The parents completed a questionnaire
concerning their child’s age, gender, general medical history,
AGE symptoms at presentation and date of onset of symp-
toms, previous RV vaccination, etc. The parents were asked to
monitor GE symptoms and the condition and temperature of
their child for the 13–18 days following enrolment. About
2 weeks after the consultation the investigator made a fol-
low-up phone call to record the duration of diarrhea and
vomiting and the maximum number of episodes of diarrhea
and vomiting experienced per 24 hours during this observa-
tion period. The severity of the AGE case was assessed by
means of the 20-point Vesikari scale, which is based on the
intensity and duration of vomiting and diarrhea, intensity of
fever and dehydration, and need for treatment and hospitali-
zation (with the severity categories defined as: score ≤ 6: mild;
score 7–10: moderate; score ≥ 11: severe).11 The severity
scoring was performed by the investigator during the follow-
up phone call for recording of symptoms.
Laboratory analysis
A stool sample was collected from each child at the first visit or
up to 4 days following this and was immediately tested for RV
either at the clinic or during the home visit using a rapid visual
immunochromatographic test kit with a sensitivity of 99.1% and
specificity > 99.9% (IMMUNOQUICK-RV, Biosynex, France).25
The samples were not tested for other intestinal pathogens. In
case the test could not be performed immediately after collec-
tion, the sample could be stored in a refrigerator for up to
24 hours at 2–8°C and tested when convenient.
Statistical analysis
Studies in various European countries of children under the
age of 5 years presenting in primary care with AGE have
shown highly varying proportions of RVGE among these,
ranging from 7.7% to 55%.22,26 Assuming an expected
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RVGE/AGE proportion of around 35% and an acceptable
width of the 95% confidence interval (CI) of ≤10%-points,
we considered that an evaluable sample of 700 patients would
allow us to estimate the actual proportion of RVGE cases with
sufficient precision, given the variability observed in the stu-
dies mentioned and given that the incidence of RV is known
to vary substantially from year to year.22 Assuming that some
10% of the patients consenting to participate would be non-
evaluable, we set the target sample size to 780.
The analysis was performed on all the enrolled patients, who
complied with the procedures stipulated in the protocol and who
had data available. The associations between disease symptoms
and RV status and between hospitalization and RV status were
analyzed by multivariate logistic regression modelling with Wald
test of the significance of the coefficients. The variables included in
these regression analyses comprised symptoms (present/absent),
age, gender, Vesikari score, and RV-status. Differences with
respect to categorical variables were tested by Chi-square tests
and Student’s t-test was used for continuous variables (mean
hospital days for admitted children). The statistical analyses were
performed using SAS version 9.2.
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